BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28233680)

  • 1. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
    Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
    Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
    Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
    Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
    Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
    Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule modulators of Wnt/β-catenin signaling.
    Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
    Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
    Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.
    Chen M; Wang J; Lu J; Bond MC; Ren XR; Lyerly HK; Barak LS; Chen W
    Biochemistry; 2009 Nov; 48(43):10267-74. PubMed ID: 19772353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
    Wei W; Liu H; Yuan J; Yao Y
    Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
    Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
    Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
    Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
    Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions.
    Zhao J; He Q; Gong Z; Chen S; Cui L
    Springerplus; 2016; 5(1):1436. PubMed ID: 27652012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
    Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
    Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
    Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
    Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
    Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
    Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
    Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
    J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.